Endometrial cancer immunotherapy chemotherapy combination FDA approval with checkpoint inhibitor treatment
RegulatoryBusiness Wire

Merck Receives FDA Approval for Keytruda Plus Chemotherapy in Advanced Endometrial Cancer

Merck announces FDA approval of pembrolizumab plus chemotherapy for adults with primary advanced or recurrent endometrial carcinoma.

Merck today announced that the FDA has approved KEYTRUDA (pembrolizumab) plus carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adults with primary advanced or recurrent endometrial carcinoma. In the Phase 3 KEYNOTE-868 trial, KEYTRUDA plus chemotherapy demonstrated a statistically significant improvement in progression-free survival and overall survival compared to placebo plus chemotherapy. This approval establishes KEYTRUDA plus chemotherapy as a new standard of care in advanced endometrial cancer.

Original Source

Business Wire
Share:

Previous

Merck Receives FDA Approval for Keytruda in Malignant Pleural Mesothelioma

Next

Gilead Sciences Announces Phase 3 Comparison of Biktarvy vs Long-Acting Injectable HIV Therapy